Global CTL019
Contact
Description
The purpose of this study is to evaluate the efficacy of Cart 19 cells therapy as measured by overall remission rate, which includes Complete Remission and Complete Remission with incomplete blood count recovery assessment in infants to adults. This study involves administer of the study drug, chemotherapy, and blood draws Reimbursement for travel may be provided. If you have questions or would like to learn more about the study, please contact the Principal Investigator, Dr. Grupp at (215) 590-5475.
Eligibility and criteria
IRB Number:
14-011485
Eligible age range:
Clinical trial phase:
Phase II
Official title:
We need families like you
Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.